Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Summers

Showing results (781-790 of 1,025) with videos related to

Pageof 103
Sort By:
Nature Communications|October 5, 2023
Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemiaHope Mumme, Beena E Thomas, Swati S Bhasin, et al.
American Journal of Respiratory and Critical Care Medicine|May 5, 2026
Increasing protein dose does not further augment muscle protein synthesis in critical illness: A Randomized, Controlled Clinical TrialMatthew J Summers, Imre W K Kouw, Imogen E Asser, et al.
Trials|February 6, 2025
TARGET Protein: the effect of augmented administration of enteral protein to critically ill adults on clinical outcomes-statistical analysis plan for a cluster randomized, cross-sectional, double cross-over, clinical trialSophie Zaloumis, Matthew J Summers, Jeffrey J Presneill, et al.
The Journal of Clinical Investigation|November 29, 2012
Circulating αKlotho influences phosphate handling by controlling FGF23 productionRosamund C Smith, Linda M O'Bryan, Emily G Farrow, et al.
Critical Care and Resuscitation : Journal of the Australasian Academy of Critical Care Medicine|October 25, 2023
Study protocol for TARGET protein: The effect of augmented administration of enteral protein to critically ill adults on clinical outcomes: A cluster randomised, cross-sectional, double cross-over, clinical trialMatthew J Summers, Lee-Anne S Chapple, Rinaldo Bellomo, et al.
JAMA|June 11, 2025
Augmented Enteral Protein During Critical Illness: The TARGET Protein Randomized Clinical TrialMatthew J Summers, Lee-Anne S Chapple, Amalia Karahalios, et al.
BMJ Open Diabetes Research & Care|November 16, 2021
Deletion of GPR21 improves glucose homeostasis and inhibits the CCL2-CCR2 axis by divergent mechanismsDarren M Riddy, Helene L Kammoun, Andrew J Murphy, et al.
Journal of the National Cancer Institute|January 10, 2023
Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400IJoseph M Unger, Lu Qian, Mary W Redman, et al.
Journal of the American Society of Nephrology : JASN|September 13, 2019
AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac FibrosisBryna S M Chow, Martina Kocan, Matthew Shen, et al.
Molecular Metabolism|May 25, 2024
The novel adrenergic agonist ATR-127 targets skeletal muscle and brown adipose tissue to tackle diabesity and steatohepatitisEmanuela Talamonti, Jelena Davegardh, Anastasia Kalinovich, et al.
Pageof 103

Showing results (781-790 of 1,025) with videos related to

Sort By:
Pageof 103
Nature Communications|October 5, 2023
Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemiaHope Mumme, Beena E Thomas, Swati S Bhasin, et al.
American Journal of Respiratory and Critical Care Medicine|May 5, 2026
Increasing protein dose does not further augment muscle protein synthesis in critical illness: A Randomized, Controlled Clinical TrialMatthew J Summers, Imre W K Kouw, Imogen E Asser, et al.
Trials|February 6, 2025
TARGET Protein: the effect of augmented administration of enteral protein to critically ill adults on clinical outcomes-statistical analysis plan for a cluster randomized, cross-sectional, double cross-over, clinical trialSophie Zaloumis, Matthew J Summers, Jeffrey J Presneill, et al.
The Journal of Clinical Investigation|November 29, 2012
Circulating αKlotho influences phosphate handling by controlling FGF23 productionRosamund C Smith, Linda M O'Bryan, Emily G Farrow, et al.
Critical Care and Resuscitation : Journal of the Australasian Academy of Critical Care Medicine|October 25, 2023
Study protocol for TARGET protein: The effect of augmented administration of enteral protein to critically ill adults on clinical outcomes: A cluster randomised, cross-sectional, double cross-over, clinical trialMatthew J Summers, Lee-Anne S Chapple, Rinaldo Bellomo, et al.
JAMA|June 11, 2025
Augmented Enteral Protein During Critical Illness: The TARGET Protein Randomized Clinical TrialMatthew J Summers, Lee-Anne S Chapple, Amalia Karahalios, et al.
BMJ Open Diabetes Research & Care|November 16, 2021
Deletion of GPR21 improves glucose homeostasis and inhibits the CCL2-CCR2 axis by divergent mechanismsDarren M Riddy, Helene L Kammoun, Andrew J Murphy, et al.
Journal of the National Cancer Institute|January 10, 2023
Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400IJoseph M Unger, Lu Qian, Mary W Redman, et al.
Journal of the American Society of Nephrology : JASN|September 13, 2019
AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac FibrosisBryna S M Chow, Martina Kocan, Matthew Shen, et al.
Molecular Metabolism|May 25, 2024
The novel adrenergic agonist ATR-127 targets skeletal muscle and brown adipose tissue to tackle diabesity and steatohepatitisEmanuela Talamonti, Jelena Davegardh, Anastasia Kalinovich, et al.
Pageof 103